Spago Nanomedical

Spago Nanomedical is active in biotechnology. The company develops nanomedicine for the diagnosis and treatment of life-threatening diseases. The company's main activities are focused on developing a cancer-selective contrast agent for magnetic resonance imaging (MRI), as well as a product for radionuclide treatment of cancer. Both of these projects are based on proprietary nanomaterials. The largest operations are in the Nordic market, with the headquarters located in Lund.